Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33.

• Crossref
• PubMed
Siegel RL, Miller KD, Fuchs HE, Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33.3502020410.3322/caac.21708)| false
• Search Google Scholar
• Export Citation

National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts. Bladder Cancer. Accessed April 27, 2022. Available at: https://seer.cancer.gov/statfacts/html/urinb.html

• PubMed
National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts. Bladder Cancer. Accessed April 27, 2022. Available at: https://seer.cancer.gov/statfacts/html/urinb.html)| false
• Search Google Scholar
• Export Citation

American Urological Association. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO joint guideline (2020). Accessed April 27, 2022. Available at: https://www.auanet.org/guidelines/bladder-cancer-non-muscle-invasive-guideline

• PubMed
American Urological Association. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO joint guideline (2020). Accessed April 27, 2022. Available at: https://www.auanet.org/guidelines/bladder-cancer-non-muscle-invasive-guideline)| false
• Search Google Scholar
• Export Citation

Ritch CR, Velasquez MC, Kwon D, et al. Use and validation of the AUA/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J Urol 2020;203:505–511.

• Crossref
• PubMed
Ritch CR, Velasquez MC, Kwon D, Use and validation of the AUA/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J Urol 2020;203:505–511.10.1097/JU.0000000000000593)| false
• Search Google Scholar
• Export Citation

Ramírez-Backhaus M, Domínguez-Escrig J, Collado A, et al. Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer. Curr Urol Rep 2012;13:109–114.

• Crossref
• PubMed
Ramírez-Backhaus M, Domínguez-Escrig J, Collado A, Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer. Curr Urol Rep 2012;13:109–114.2236755810.1007/s11934-012-0234-4)| false
• Search Google Scholar
• Export Citation

Divrik RT, Yildirim U, Zorlu F, et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006;175:1641–1644.

• Crossref
• PubMed
Divrik RT, Yildirim U, Zorlu F, The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006;175:1641–1644.1660072010.1016/S0022-5347(05)01002-5)| false
• Search Google Scholar
• Export Citation

Eroglu A, Ekin RG, Koc G, et al. The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial. Int J Clin Oncol 2020;25:698–704.

• Crossref
• PubMed
Eroglu A, Ekin RG, Koc G, The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial. Int J Clin Oncol 2020;25:698–704.3176052410.1007/s10147-019-01581-0)| false
• Search Google Scholar
• Export Citation

Grimm MO, Steinhoff C, Simon X, et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170:433–437.

• Crossref
• PubMed
Grimm MO, Steinhoff C, Simon X, Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170:433–437.1285379310.1097/01.ju.0000070437.14275.e0)| false
• Search Google Scholar
• Export Citation

Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74–76.

• Crossref
• PubMed
Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74–76.10.1097/00005392-199907000-0001810379743)| false
• Search Google Scholar
• Export Citation

Petrelli F, Giannatempo P, Maccagnano C, et al. Active surveillance for non-muscle invasive bladder cancer: a systematic review and pooled-analysis. Cancer Treat Res Commun 2021;27:100369.

• Crossref
• PubMed
Petrelli F, Giannatempo P, Maccagnano C, Active surveillance for non-muscle invasive bladder cancer: a systematic review and pooled-analysis. Cancer Treat Res Commun 2021;27:100369.10.1016/j.ctarc.2021.10036933838570)| false
• Search Google Scholar
• Export Citation

Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 2016;69:231–244.

• PubMed
Sylvester RJ, Oosterlinck W, Holmang S, Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 2016;69:231–244.26091833)| false
• Search Google Scholar
• Export Citation

Laukhtina E, Abufaraj M, Al-Ani A, et al. Intravesical therapy in patients with intermediate-risk non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence. Eur Urol Focus 2022;8:447–456.

• Crossref
• PubMed
Laukhtina E, Abufaraj M, Al-Ani A, Intravesical therapy in patients with intermediate-risk non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence. Eur Urol Focus 2022;8:447–456.3376220310.1016/j.euf.2021.03.016)| false
• Search Google Scholar
• Export Citation

Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462–472.

• Crossref
• PubMed
Oddens J, Brausi M, Sylvester R, Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462–472.10.1016/j.eururo.2012.10.03923141049)| false
• Search Google Scholar
• Export Citation

Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–465, discussion 475–477.

• Crossref
• PubMed
Sylvester RJ, van der Meijden AP, Oosterlinck W, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–465, discussion 475–477.10.1016/j.eururo.2005.12.03116442208)| false
• Search Google Scholar
• Export Citation

Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 2001;21:765–769.

• PubMed
Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 2001;21:765–769.11299841)| false
• Search Google Scholar
• Export Citation

Huncharek M, Geschwind JF, Witherspoon B, et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 2000;53:676–680.

• Crossref
• PubMed
Huncharek M, Geschwind JF, Witherspoon B, Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 2000;53:676–680.10.1016/S0895-4356(99)00203-610941943)| false
• Search Google Scholar
• Export Citation

Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90–95.

• Crossref
• PubMed
Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90–95.1247811110.1016/S0022-5347(05)64043-8)| false
• Search Google Scholar
• Export Citation

Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216–1223.

• Crossref
• PubMed
Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216–1223.10.1016/j.urology.2005.12.01416765182)| false
• Search Google Scholar
• Export Citation

Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209–216.

• Crossref
• PubMed
Shelley MD, Kynaston H, Court J, A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209–216.1148873110.1046/j.1464-410x.2001.02306.x)| false
• Search Google Scholar
• Export Citation

Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485–490.

• Crossref
• PubMed
Shelley MD, Wilt TJ, Court J, Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485–490.10.1111/j.1464-410X.2003.04655.x15008714)| false
• Search Google Scholar
• Export Citation

Amin MB, Edge SB, Greene F, et al., eds. AJCC Cancer Staging Manual, 8th ed. New York, NY:Springer International Publishing; 2017.

• Crossref
• PubMed
Amin MB, Edge SB, Greene F, , eds. AJCC Cancer Staging Manual, 8th ed. New York, NY:Springer International Publishing; 2017.10.1007/978-3-319-40618-3)| false
• Search Google Scholar
• Export Citation

Mirabal JR, Taylor JA, Lerner SP. CIS of the bladder: significance and implications for therapy. Bladder Cancer 2019;5:193–204.

• Crossref
• PubMed
Mirabal JR, Taylor JA, Lerner SP. CIS of the bladder: significance and implications for therapy. Bladder Cancer 2019;5:193–204.10.3233/BLC-190236)| false
• Search Google Scholar
• Export Citation

Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021;22:919–930.

• Crossref
• PubMed
Balar AV, Kamat AM, Kulkarni GS, Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021;22:919–930.3405117710.1016/S1470-2045(21)00147-9)| false
• Search Google Scholar
• Export Citation

Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:1296–1299.

• Crossref
• PubMed
Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:1296–1299.10.1016/S0022-5347(05)65756-411547061)| false
• Search Google Scholar
• Export Citation

Mari A, Kimura S, Foerster B, et al. A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU Int 2019;123:11–21.

• Crossref
• PubMed
Mari A, Kimura S, Foerster B, A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU Int 2019;123:11–21.2980738710.1111/bju.14417)| false
• Search Google Scholar
• Export Citation

Catto JWF, Gordon K, Collinson M, et al. Radical cystectomy against intravesical BCG for High-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study. J Clin Oncol 2021;39:202–214.

• Crossref
• PubMed
Catto JWF, Gordon K, Collinson M, Radical cystectomy against intravesical BCG for High-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study. J Clin Oncol 2021;39:202–214.10.1200/JCO.20.0166533332191)| false
• Search Google Scholar
• Export Citation

American Urological Association. BCG Shortage Notice. Accessed April 27, 2022. Available at: https://www.auanet.org/bcg-shortage-notice

• PubMed
American Urological Association. BCG Shortage Notice. Accessed April 27, 2022. Available at: https://www.auanet.org/bcg-shortage-notice)| false
• Search Google Scholar
• Export Citation

Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010;116:1893–1900.

• Crossref
• PubMed
Di Lorenzo G, Perdonà S, Damiano R, Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010;116:1893–1900.10.1002/cncr.2491420162706)| false
• Search Google Scholar
• Export Citation

Jones G, Cleves A, Wilt TJ, et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev 2012;1:CD009294.

• PubMed
Jones G, Cleves A, Wilt TJ, Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev 2012;1:CD009294.22259002)| false
• Search Google Scholar
• Export Citation

Friedrich MG, Pichlmeier U, Schwaibold H, et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007;52:1123–1129.

• Crossref
• PubMed
Friedrich MG, Pichlmeier U, Schwaibold H, Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007;52:1123–1129.1738308010.1016/j.eururo.2007.02.063)| false
• Search Google Scholar
• Export Citation

Chou R, Selph S, Buckley DI, et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol 2017;197:1189–1199.

• Crossref
• PubMed
Chou R, Selph S, Buckley DI, Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol 2017;197:1189–1199.2802786810.1016/j.juro.2016.12.090)| false
• Search Google Scholar
• Export Citation

Sylvester RJ, van der Meijden AP, Witjes JA, et al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86–91, discussion 91–92.

• Crossref
• PubMed
Sylvester RJ, van der Meijden AP, Witjes JA, Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86–91, discussion 91–92.10.1097/01.ju.0000162059.64886.1c15947584)| false
• Search Google Scholar
• Export Citation

Milbar N, Kates M, Chappidi MR, et al. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer 2017;3:293–303.

• Crossref
• PubMed
Milbar N, Kates M, Chappidi MR, Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer 2017;3:293–303.2915255310.3233/BLC-170126)| false
• Search Google Scholar
• Export Citation

Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766–773.

• PubMed
Sylvester RJ, Brausi MA, Kirkels WJ, Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766–773.20034729)| false
• Search Google Scholar
• Export Citation

van der Meijden AP, Brausi M, Zambon V, et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001;166:476–481.

• PubMed
van der Meijden AP, Brausi M, Zambon V, Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001;166:476–481.11458050)| false
• Search Google Scholar
• Export Citation

Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;163:761–767.

• Crossref
• PubMed
Steinberg G, Bahnson R, Brosman S, Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;163:761–767.10.1016/S0022-5347(05)67799-3)| false
• Search Google Scholar
• Export Citation

Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 2009;27:331–335.

• Crossref
• PubMed
Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 2009;27:331–335.1921452810.1007/s00345-009-0377-1)| false
• Search Google Scholar
• Export Citation

Breyer BN, Whitson JM, Carroll PR, et al. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol 2010;28:510–514.

• Crossref
• PubMed
Breyer BN, Whitson JM, Carroll PR, Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol 2010;28:510–514.10.1016/j.urolonc.2008.11.01919171491)| false
• Search Google Scholar
• Export Citation

Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 2020;203:902–909.

• Crossref
• PubMed
Steinberg RL, Thomas LJ, Brooks N, Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 2020;203:902–909.10.1097/JU.000000000000068831821066)| false
• Search Google Scholar
• Export Citation

Steinberg RL, Packiam VT, Thomas LJ, et al. Intravesical sequential gemcitabine and docetaxel versus bacillus Calmette-Guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urol Oncol 2022;40:9.e1–9.e7.

• Crossref
• PubMed
Steinberg RL, Packiam VT, Thomas LJ, Intravesical sequential gemcitabine and docetaxel versus bacillus Calmette-Guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urol Oncol 2022;40:9.e1–9.e7.10.1016/j.urolonc.2021.03.024)| false
• Search Google Scholar
• Export Citation

Klaassen Z, Kamat AM, Kassouf W, et al. Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations. Eur Urol 2018;74:597–608.

• Crossref
• PubMed
Klaassen Z, Kamat AM, Kassouf W, Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations. Eur Urol 2018;74:597–608.10.1016/j.eururo.2018.06.02430017405)| false
• Search Google Scholar
• Export Citation

Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174:1242–1247.

• Crossref
• PubMed
Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174:1242–1247.10.1097/01.ju.0000173919.28835.aa)| false
• Search Google Scholar
• Export Citation

Pfister C, Kerkeni W, Rigaud J, et al. Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol 2015;22:53–60.

• Crossref
• PubMed
Pfister C, Kerkeni W, Rigaud J, Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol 2015;22:53–60.10.1111/iju.12609)| false
• Search Google Scholar
• Export Citation

Yokomizo A, Kanimoto Y, Okamura T, et al. Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Guérin instillation therapy for nonmuscle invasive bladder cancer. J Urol 2016;195:41–46.

• Crossref
• PubMed
Yokomizo A, Kanimoto Y, Okamura T, Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Guérin instillation therapy for nonmuscle invasive bladder cancer. J Urol 2016;195:41–46.10.1016/j.juro.2015.08.07526307162)| false
• Search Google Scholar
• Export Citation

Joudi FN, Smith BJ, O’Donnell MA; National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006;24:344–348.

• Crossref
• PubMed
Joudi FN, Smith BJ, O’Donnell MA; National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006;24:344–348.1681818910.1016/j.urolonc.2005.11.026)| false
• Search Google Scholar
• Export Citation

Steinberg RL, Brooks NA, Thomas LJ, et al. Bacillus Calmette-Guerin strain may not affect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer. Urol Oncol 2017;35:201–207.

• Crossref
• PubMed
Steinberg RL, Brooks NA, Thomas LJ, Bacillus Calmette-Guerin strain may not affect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer. Urol Oncol 2017;35:201–207.2804199810.1016/j.urolonc.2016.11.016)| false
• Search Google Scholar
• Export Citation

O’Donnell MA, Lilli K, Leopold C; National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004;172:888–893.

• Crossref
• PubMed
O’Donnell MA, Lilli K, Leopold C; National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004;172:888–893.1531099110.1097/01.ju.0000136446.37840.0a)| false
• Search Google Scholar
• Export Citation

Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021;384:2102–2114.

• Crossref
• PubMed
Bajorin DF, Witjes JA, Gschwend JE, Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021;384:2102–2114.3407764310.1056/NEJMoa2034442)| false
• Search Google Scholar
• Export Citation

Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383:1218–1230.

• Crossref
• PubMed
Powles T, Park SH, Voog E, Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383:1218–1230.10.1056/NEJMoa2002788)| false
• Search Google Scholar
• Export Citation

Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 2017;18:212–220.

• Crossref
• PubMed
Plimack ER, Bellmunt J, Gupta S, Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 2017;18:212–220.10.1016/S1470-2045(17)30007-428081914)| false
• Search Google Scholar
• Export Citation

Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–1026.

• Crossref
• PubMed
Bellmunt J, de Wit R, Vaughn DJ, Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–1026.2821206010.1056/NEJMoa1613683)| false
• Search Google Scholar
• Export Citation

Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 2019;30:970–976.

• Crossref
• PubMed
Fradet Y, Bellmunt J, Vaughn DJ, Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 2019;30:970–976.3105070710.1093/annonc/mdz127)| false
• Search Google Scholar
• Export Citation

Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016;34:3119–3125.

• Crossref
• PubMed
Massard C, Gordon MS, Sharma S, Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016;34:3119–3125.2726993710.1200/JCO.2016.67.9761)| false
• Search Google Scholar
• Export Citation

Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol 2017;3:e172411.

• Crossref
• PubMed
Powles T, O’Donnell PH, Massard C, Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol 2017;3:e172411.10.1001/jamaoncol.2017.2411)| false
• Search Google Scholar
• Export Citation

Broderick JM. Durvalumab FDA indication for bladder cancer voluntarily withdrawn. Urology Times. February 22, 2021. Accessed April 28, 2022. Available at: https://www.urologytimes.com/view/durvalumab-fda-indication-for-bladder-cancer-voluntarily-withdrawn

• PubMed
Broderick JM. Durvalumab FDA indication for bladder cancer voluntarily withdrawn. Urology Times. February 22, 2021. Accessed April 28, 2022. Available at: https://www.urologytimes.com/view/durvalumab-fda-indication-for-bladder-cancer-voluntarily-withdrawn)| false
• Search Google Scholar
• Export Citation

Powles T, van der Heijden MS, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2020;21:1574–1588.

• Crossref
• PubMed
Powles T, van der Heijden MS, Castellano D, Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2020;21:1574–1588.10.1016/S1470-2045(20)30541-632971005)| false
• Search Google Scholar
• Export Citation

Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–1920.

• Crossref
• PubMed
Rosenberg JE, Hoffman-Censits J, Powles T, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–1920.2695254610.1016/S0140-6736(16)00561-4)| false
• Search Google Scholar
• Export Citation

Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748–757.

• Crossref
• PubMed
Powles T, Durán I, van der Heijden MS, Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748–757.2926894810.1016/S0140-6736(17)33297-X)| false
• Search Google Scholar
• Export Citation

The ASCO Post Staff. Atezolizumab’s indication in previously treated metastatic bladder cancer is withdrawn. Accessed April 28, 2022. Available at: https://ascopost.com/news/march-2021/atezolizumab-s-indication-in-previously-treated-metastatic-bladder-cancer-is-withdrawn/

• PubMed
The ASCO Post Staff. Atezolizumab’s indication in previously treated metastatic bladder cancer is withdrawn. Accessed April 28, 2022. Available at: https://ascopost.com/news/march-2021/atezolizumab-s-indication-in-previously-treated-metastatic-bladder-cancer-is-withdrawn/)| false
• Search Google Scholar
• Export Citation

Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 2019;37:2592–2600.

• Crossref
• PubMed
Rosenberg JE, O’Donnell PH, Balar AV, Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 2019;37:2592–2600.3135614010.1200/JCO.19.01140)| false
• Search Google Scholar
• Export Citation

Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384:1125–1135.

• Crossref
• PubMed
Powles T, Rosenberg JE, Sonpavde GP, Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384:1125–1135.10.1056/NEJMoa203580733577729)| false
• Search Google Scholar
• Export Citation

Yu EY, Petrylak DP, O’Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2021;22:872–882.

• Crossref
• PubMed
Yu EY, Petrylak DP, O’Donnell PH, Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2021;22:872–882.10.1016/S1470-2045(21)00094-233991512)| false
• Search Google Scholar
• Export Citation

Rosenberg J, Sridhar SS, Zhang J, et al. EV-101: a phase i study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol 2020;38:1041–1049.

• Crossref
• PubMed
Rosenberg J, Sridhar SS, Zhang J, EV-101: a phase i study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol 2020;38:1041–1049.3203189910.1200/JCO.19.02044)| false
• Search Google Scholar
• Export Citation

U.S. Food and Drug Administration. Enfortumab vedotin-ejfv for injection, for intravenous use [prescribing information]. Accessed April 27, 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s006s008lbl.pdf

• PubMed
U.S. Food and Drug Administration. Enfortumab vedotin-ejfv for injection, for intravenous use [prescribing information]. Accessed April 27, 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s006s008lbl.pdf)| false
• Search Google Scholar
• Export Citation

Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 2021;39:2474–2485.

• Crossref
• PubMed
Tagawa ST, Balar AV, Petrylak DP, TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 2021;39:2474–2485.10.1200/JCO.20.0348933929895)| false
• Search Google Scholar
• Export Citation